Senate committee hears hours of testimony on clinician‑led psilocybin program bill
Senate Health and Long Term Care Committee heard extensive testimony for and against SB 5921, which would create a Department of Health‑regulated medical psilocybin program effective 07/01/2028; proponents cited clinical trial promise and veterans’ stories, while medical groups warned safeguards and workforce scope need tightening.
The full story
The Washington Senate Health and Long Term Care Committee on Jan. 27 heard hours of public testimony on Senate Bill 5921, a proposal to create a clinician‑led, Department of Health‑regulated medical psilocybin program.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.
or
Free account
Keep reading for free
Create a free account to finish this story and see the video, transcript and key details.
Continue with GoogleContinue with emailAlready have an account? Log in